Full Year 2024 EBOS Group Ltd Earnings Call Transcript
Key Points
- Ebos Group Ltd (EBOSY) achieved a 7.8% increase in revenue, reaching $13.2 billion for FY24.
- Underlying EBITDA grew by 7.3% to $624 million, indicating strong operational performance.
- The Healthcare segment saw a 6% increase in underlying EBITDA, driven by 9.4% growth in the Australian business.
- Animal Care segment experienced a 13% increase in underlying EBITDA, supported by resilience in the pet food category and new product launches.
- The company declared a final dividend of NZD 0.615 per share, bringing the full-year dividends to NZD 1.185 per share, a 7.7% increase from the previous year.
- The conclusion of the Chemist Warehouse Australia contract at the end of FY24 resulted in a normalization of EBITDA growth to approximately 8%.
- New Zealand's Healthcare performance was impacted by a decline in nonrecurring COVID-19 activity within the Contract Logistics division.
- The wholesale business Lyppard saw a 4% decline in revenue due to a key supplier bypassing the wholesale channel.
- The company experienced a reduction in GOR for Contract Logistics in New Zealand due to decreased activity related to COVID-19 products.
- Net debt increased by over $250 million compared to the prior year, largely due to M&A investments, bringing the total net debt to just over $1 billion.
Thank you for standing by, and welcome to the EBOS Group Limited full-year 2024 results conference. (Operator Instructions) I must advise you that this conference is being recorded today, the 21 of August 2024.
I would now like to hand the conference over to your speaker today, Mr. John Cullity, CEO, EBOS Group. Please go ahead John.
Thank you, Daniel, and welcome, everyone, to EBOS Group's full-year 2024 results presentation. As Daniel said, my name is John Cullity, the CEO of the Group. And I'm joined this morning by both Leonard Hansen, our CFO; and Martin Krauskopf, our EGM for M&A and Investor Relations.
I'm very pleased to report that EBOS has achieved another year of strong growth. The key financial headlines for FY24 revenue increased by 7.8% to $13.2 billion. Underlying EBITDA increased by 7.3% to $624 million. Underlying net profit after tax increased by 7.7% to $303 million and underlying earnings per share increased by 6.8% to $1.579.
Our balance sheet
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
